Bristol Myers drug delays myeloma progression in hard to treat patients

Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed ​or not responded to other treatments.